

FIG. 1B




FIG. 1C





FIG. 1A






FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B

Parameter (Units)	Treatment	N	Geometric LS Mean	Comparison of Treatment Groups	
				Geometric Mean Ratio (90% CI)	
AUCinf (h*µmol/L)	Treatment B	10	12600	98.10 (89.26, 107.83)	
	Treatment A1	10	12840		
	Treatment D	10	13460	104.82 (96.08, 114.36)	
	Treatment A1	10	12840		
AUClast (h*µmol/L)	Treatment B	10	12130	96.41 (86.59, 107.34)	
	Treatment A1	10	12580		
	Treatment D	10	13000	103.29 (93.55, 114.03)	
	Treatment A1	10	12580		
Cmax (nmol/L)	Treatment B	10	2272	86.20 (65.92, 112.72)	
	Treatment A1	10	2636		
	Treatment D	10	2447	92.82 (72.49, 118.85)	
	Treatment A1	10	2636		
C24 (nmol/L)	Treatment B	10	67.94	148.86 (101.28, 218.77)	
	Treatment A1	10	45.64		
	Treatment D	10	56.22	123.17 (86.40, 175.60)	
	Treatment A1	10	45.64		

Treatment A1 150 mg AZD9977 (AZD9977 capsule 50 mg + AZD9977 capsule 100 mg) and 10 mg dapagliflozin tablet, fasted in Group 1. Treatment B 150 mg AZD9977 + 10 mg dapagliflozin Capsule 1, fasted. Treatment D 150 mg AZD9977 + 10 mg dapagliflozin Capsule 2, fasted. CI Confidence interval. LS Least-squares; N Number of subjects per treatment group. Geometric mean ratio and corresponding 90% CI are back-transformed.

Result based on a linear mixed effect analysis of variance (ANOVA) of log transformed PK parameter with sequence, period, treatment as fixed-effect and subject nested within sequence as random effect.

FIG. 4A

Parameter (Units)	Treatment	N	Geometric LS Mean	Comparison of Treatment Groups	
				Geometric Mean Ratio (90% CI)	
AUCinf (h*umol/L)	Treatment C	10	14870	118.07 (108.27, 128.76)	
	Treatment B	10	12600		
	Treatment E	10	13750		
	Treatment D	10	13460		
AUClast (h*umol/L)	Treatment C	10	14710	121.24 (109.87, 133.79)	
	Treatment B	10	12130		
	Treatment E	10	13510		
	Treatment D	10	13000		
Cmax (umol/L)	Treatment C	10	3531	156.28 (122.20, 199.86)	
	Treatment B	10	2272		
	Treatment E	10	3195		
	Treatment D	10	2447		
C24 (umol/L)	Treatment C	10	20.88	30.73 (21.60, 43.72)	
	Treatment B	10	67.94		
	Treatment E	9	24.76		
	Treatment D	10	56.22		

Treatment B 150 mg AZD9977 + 10 mg dapagliflozin Capsule 1, fasted. Treatment C 150 mg AZD9977 + 10 mg dapagliflozin Capsule 1, fed. Treatment D 150 mg AZD9977 + 10 mg dapagliflozin Capsule 2, fasted. Treatment E 150 mg AZD9977 + 10 mg dapagliflozin Capsule 2, fed. CI Confidence interval, LS Least-squares, N Number of subjects per treatment group. Geometric mean ratio and corresponding 90% CI are back-transformed.

Result based on a linear mixed effect analysis of variance (ANOVA) of log transformed PK parameter with sequence, period, treatment as fixed-effect and subject nested within sequence as random effect.

FIG. 4B

Parameter (Units)	Treatment	N	Geometric LS Mean	Comparison of Treatment Groups
				Geometric Mean Ratio (90% CI)
AUCinf (h*nmol/L)	Treatment F	10	15400	104.31 (98.64, 110.29)
	Treatment A2	10	14760	
	Treatment G	10	15510	
	Treatment A2	10	14760	
AUClast (h*nmol/L)	Treatment F	10	14770	102.50 (95.22, 110.33)
	Treatment A2	10	14410	
	Treatment G	10	14900	
	Treatment A2	10	14410	
Cmax (nmol/L)	Treatment F	10	2552	89.63 (70.83, 113.57)
	Treatment A2	10	2845	
	Treatment G	10	2399	
	Treatment A2	10	2845	
C24 (nmol/L)	Treatment F	10	80.03	110.97 (64.09, 192.14)
	Treatment A2	10	72.12	
	Treatment G	10	103.0	
	Treatment A2	10	72.12	

Treatment A2 150 mg AZD9977 (AZD9977 capsule 50 mg + AZD9977 capsule 100 mg) and 10 mg dapagliflozin tablet, fasted in Group 2. Treatment F 150 mg AZD9977 + 10 mg dapagliflozin Capsule 3, fasted. Treatment G 150 mg AZD9977 + 10 mg dapagliflozin Capsule 4, fasted. CI Confidence interval. LS Least-squares; N Number of subjects per treatment group. Geometric mean ratio and corresponding 90% CI are back-transformed. Result based on a linear mixed effect analysis of variance (ANOVA) of log transformed PK parameter with sequence, period, treatment as fixed-effect and subject nested within sequence as random effect.

FIG. 5A

Parameter (Units)	Treatment	N	Geometric LS Mean	Comparison of Treatment Groups	
				Geometric Mean Ratio (90% CI)	
AUCinf (h*nmol/L)	Treatment B	10	13300	97.10 (88.43, 106.63)	
	Treatment F	10	13700		
	Treatment D	10	14140	102.97 (93.39, 113.54)	
	Treatment G	10	13740		
AUClast (h*nmol/L)	Treatment B	10	12800	97.33 (87.55, 108.20)	
	Treatment F	10	13150		
	Treatment D	10	13580	102.82 (92.03, 114.87)	
	Treatment G	10	13210		
Cmax (nmol/L)	Treatment B	10	2366	101.64 (79.49, 129.97)	
	Treatment F	10	2328		
	Treatment D	10	2429	111.17 (85.56, 144.45)	
	Treatment G	10	2185		
C24 (nmol/L)	Treatment B	10	73.60	99.02 (64.74, 151.47)	
	Treatment F	10	74.32		
	Treatment D	10	67.35	70.72 (44.92, 111.35)	
	Treatment G	10	95.23		

Treatment B 150 mg AZD9977 + 10 mg dapagliflozin Capsule 1, fasted. Treatment D 150 mg AZD9977 + 10 mg dapagliflozin Capsule 2, fasted. Treatment F 150 mg AZD9977 + 10 mg dapagliflozin Capsule 3, fasted. Treatment G 150 mg AZD9977 + 10 mg dapagliflozin Capsule 4, fasted. CI Confidence interval; LS Least-squares; N Number of subjects per treatment group.
Result based on a linear mixed effect analysis of variance (ANOVA) of log transformed PK parameter with period, treatment as fixed-effect and subject nested within sequence as random effect and adjusting for the values of reference Treatment A. Geometric mean ratio and corresponding 90% CI are back-transformed.

FIG. 5B




FIG. 6A




FIG. 6B

Parameter (Units)	Treatment	N	Geometric LS Mean	Comparison of Treatment Groups	
				Geometric Mean Ratio (90% CI)	
AUCinf (h*ng/mL)	Treatment B	10	517.2	100.17 (96.25, 104.25)	
	Treatment A1	10	516.3		
	Treatment D	10	531.5	102.95 (99.22, 106.81)	
	Treatment A1	10	516.3		
AUClast (h*ng/mL)	Treatment B	10	505.9	99.81 (95.98, 103.80)	
	Treatment A1	10	506.8		
	Treatment D	10	523.2	103.24 (99.57, 107.04)	
	Treatment A1	10	506.8		
Cmax (ng/mL)	Treatment B	10	128.5	88.96 (70.52, 112.22)	
	Treatment A1	10	144.4		
	Treatment D	10	131.3	90.94 (73.41, 112.64)	
	Treatment A1	10	144.4		
C24 (ng/mL)	Treatment B	10	4.007	106.51 (93.73, 121.03)	
	Treatment A1	10	3.762		
	Treatment D	10	4.185	111.24 (98.68, 125.14)	
	Treatment A1	10	3.762		

Treatment A1 150 mg AZD9977 (AZD9977 capsule 50 mg + AZD9977 capsule 100 mg) and 10 mg dapagliflozin tablet, fasted in Group 1. Treatment B 150 mg AZD9977 + 10 mg dapagliflozin Capsule 1, fasted. Treatment D 150 mg AZD9977 + 10 mg dapagliflozin Capsule 2, fasted. CI Confidence interval. LS Least-squares. N Number of subjects per treatment group. Geometric mean ratio and corresponding 90% CI are back-transformed.

Result based on a linear mixed effect analysis of variance (ANOVA) of log transformed PK parameter with sequence, period, treatment as fixed-effect and subject nested within sequence as random effect.

FIG. 7A

FIG. 7B

Parameter (Units)	Treatment	N	Geometric LS Mean	Comparison of Treatment Groups Geometric Mean Ratio (90% CI)
AUCinf (h*ng/mL)	Treatment C	10	536.0	103.65 (99.92, 107.52)
	Treatment B	10	517.2	
	Treatment E	10	523.4	
	Treatment D	10	531.5	
AUClast (h*ng/mL)	Treatment C	10	527.0	104.19 (100.51, 108.00)
	Treatment B	10	505.9	
	Treatment E	10	514.6	
	Treatment D	10	523.2	
Cmax (ng/mL)	Treatment C	10	84.51	85.78 (53.16, 81.39)
	Treatment B	10	128.5	
	Treatment E	10	94.73	
	Treatment D	10	131.3	
C24 (ng/mL)	Treatment C	10	4.487	111.96 (99.58, 125.89)
	Treatment B	10	4.007	
	Treatment E	10	4.242	
	Treatment D	10	4.185	

Treatment B 150 mg AZD9977 + 10 mg dapagliflozin Capsule 1, fasted. Treatment C 150 mg AZD9977 + 10 mg dapagliflozin Capsule 1, fed. Treatment D 150 mg AZD9977 + 10 mg dapagliflozin Capsule 2, fasted. Treatment E 150 mg AZD9977 + 10 mg dapagliflozin Capsule 2, fed. CI Confidence interval, LS Least-squares, N Number of subjects per treatment group. Geometric mean ratio and corresponding 90% CI are back-transformed.

Result based on a linear mixed effect analysis of variance (ANOVA) of log transformed PK parameter with sequence, period, treatment as fixed-effect and subject nested within sequence as random effect.

FIG. 8A

Parameter (Units)	Treatment	N	Geometric LS Mean	Comparison of Treatment Groups	
				Geometric Mean Ratio (90% CI)	
AUC _{inf} (h*ng/mL)	Treatment F	10	512.5	102.73 (97.82, 107.89)	
	Treatment A2	10	498.9		
	Treatment G	10	542.5	108.76 (103.53, 114.23)	
	Treatment A2	10	498.8		
	Treatment H	10	528.4	105.93 (100.86, 111.23)	
	Treatment A2	10	498.8		
AUC _{last} (h*ng/mL)	Treatment F	10	503.0	103.65 (98.05, 108.31)	
	Treatment A2	10	488.1		
	Treatment G	10	528.0	108.17 (102.90, 113.72)	
	Treatment A2	10	488.1		
	Treatment H	10	510.9	106.71 (101.53, 112.13)	
	Treatment A2	10	488.1		
C _{max} (ng/mL)	Treatment F	10	122.4	77.78 (64.90, 93.22)	
	Treatment A2	10	157.4		
	Treatment G	10	152.1	96.64 (90.56, 115.93)	
	Treatment A2	10	157.4		
	Treatment H	10	116.1	73.76 (61.54, 88.40)	
	Treatment A2	10	157.4		
C ₂₄ (ng/mL)	Treatment F	10	3.608	107.49 (97.02, 119.08)	
	Treatment A2	10	3.356		
	Treatment G	10	3.741	111.47 (100.57, 123.56)	
	Treatment A2	10	3.356		
	Treatment H	10	3.855	114.85 (103.67, 127.24)	
	Treatment A2	10	3.356		

Treatment A2 150 mg AZD9977 (AZD9977 capsule 50 mg + AZD9977 capsule 100 mg) and 10 mg dapagliflozin tablet, fasted in Group 2. Treatment F 150 mg AZD9977 + 10 mg dapagliflozin Capsule 3, fasted. Treatment G 150 mg AZD9977 + 10 mg dapagliflozin Capsule 4, fasted. Treatment H 10 mg dapagliflozin capsule, fasted. CI Confidence interval, LS Least-squares, N Number of subjects per treatment group. Geometric mean ratio and corresponding 90% CI are back-transformed.
Result based on a linear mixed effect analysis of variance (ANOVA) of log transformed PK parameter with sequence, period, treatment as fixed-effect and subject nested within sequence as random effect.

FIG. 8B

Parameter (Units)	Treatment	N	Geometric LS Mean	Comparison of Treatment Groups	
				Geometric Mean Ratio (90% CI)	
AUCinf (h*ug/mL)	Treatment B	10	517.9	93.59 (88.63, 98.82)	
	Treatment G	10	553.4		
	Treatment D	10	533.1	101.69 (96.06, 107.62)	
	Treatment F	10	524.3		
AUClast (h*ug/mL)	Treatment B	10	305.1	93.66 (88.64, 98.95)	
	Treatment G	10	539.4		
	Treatment D	10	523.6	101.58 (95.4, 107.58)	
	Treatment F	10	515.4		
Cmax (ug/mL)	Treatment B	10	138.7	84.30 (69.52, 100.22)	
	Treatment G	10	152.7		
	Treatment D	10	133.3	107.57 (87.33, 131.03)	
	Treatment F	10	124.1		
C24 (ug/mL)	Treatment B	10	3.968	101.53 (69.73, 114.89)	
	Treatment G	10	3.927		
	Treatment D	10	4.101	108.09 (94.91, 123.09)	
	Treatment F	10	3.794		

Treatment B 150 mg AZD9977 + 10 mg dapagliflozin Capsule 1, fasted, Treatment D 150 mg AZD9977 + 10 mg dapagliflozin Capsule 2, fasted, Treatment F 150 mg AZD9977 + 10 mg dapagliflozin Capsule 3, fasted, Treatment G 150 mg AZD9977 + 10 mg dapagliflozin Capsule 4, fasted, CI: Confidence interval, LS: Least-squares, N: Number of subjects per treatment group.
Result based on a linear mixed effect analysis of variance (ANOVA) of log transformed PK parameter with period, treatment as fixed effect and subject nested within sequence as random effect and adjusting for the values of reference Treatment A. Geometric mean ratio and corresponding 90% CI are back transformed.